Marshall Wace LLP Acquires 2,057,864 Shares of Chimerix, Inc. (NASDAQ:CMRX)

Marshall Wace LLP raised its holdings in Chimerix, Inc. (NASDAQ:CMRX) by 1,318.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,213,940 shares of the biopharmaceutical company’s stock after purchasing an additional 2,057,864 shares during the period. Marshall Wace LLP’s holdings in Chimerix were worth $7,705,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Assenagon Asset Management S.A. grew its stake in Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after buying an additional 496,823 shares in the last quarter. Stoneridge Investment Partners LLC grew its position in shares of Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 8,134 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Chimerix during the 4th quarter valued at $2,626,000. Valeo Financial Advisors LLC raised its stake in shares of Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC purchased a new stake in Chimerix during the 4th quarter worth about $221,000. Institutional investors own 45.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CMRX. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.50 target price (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. StockNews.com started coverage on shares of Chimerix in a report on Wednesday, April 16th. They set a “hold” rating on the stock. Wedbush reissued a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright restated a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Shares of CMRX opened at $8.54 on Wednesday. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $8.55. The company has a market cap of $801.09 million, a PE ratio of -9.09 and a beta of -0.17. The stock has a 50-day moving average price of $7.55 and a 200-day moving average price of $4.10.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. As a group, analysts predict that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.